GeneDx Holdings Corp.(WGS)
NASDAQ
$62.37
-1.99 (-3.09%)

GeneDx Holdings Corp.(WGS)Company Profile & Business
NASDAQ

Company Profile

Business overview, scale, and footprint

Company NameGeneDx Holdings Corp.
Ticker SymbolWGS
ExchangeNMS
SectorHealthcare
IndustryDiagnostics & Research
Employees1,300
CEOMs. Katherine A. Stueland
Founded2000
HeadquartersStamford, CT, United States
CountryUnited States
Websitegenedx.com
Next Earnings DateNov 9, 2026

Business Overview

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Insider Transactions

Open-market purchases and sales reported on SEC Form 4

Insider Activity Summary

On Sep 16, 2026, insiders of GeneDx Holdings Corp. (WGS) reported 10 open-market trades on SEC Form 4: 0 purchases (0 shares) and 10 sales (14,229 shares, about $1.39M). Sales exceeded purchases by about $1.39M.

10 open-market insider trades found. Showing 10 of 10.

Show:entries
Insider NameRelation to CompanyShares ChangedPriceTransaction Date
Feeley KevinCHIEF FINANCIAL OFFICER-1,079$99.00Sep 16, 2026
Feeley KevinCHIEF FINANCIAL OFFICER-1,470$98.27Sep 16, 2026
Feeley KevinCHIEF FINANCIAL OFFICER-541$96.90Sep 16, 2026
Feeley KevinCHIEF FINANCIAL OFFICER-52$95.41Sep 16, 2026
Feeley KevinCHIEF FINANCIAL OFFICER-586$94.26Sep 16, 2026
Stueland KatherineCHIEF EXECUTIVE OFFICER-3,039$99.00Sep 16, 2026
Stueland KatherineCHIEF EXECUTIVE OFFICER-4,141$98.27Sep 16, 2026
Stueland KatherineCHIEF EXECUTIVE OFFICER-1,525$96.90Sep 16, 2026
Stueland KatherineCHIEF EXECUTIVE OFFICER-148$95.41Sep 16, 2026
Stueland KatherineCHIEF EXECUTIVE OFFICER-1,648$94.26Sep 16, 2026